BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 24189654)

  • 1. Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens.
    Pritchard CC; Salipante SJ; Koehler K; Smith C; Scroggins S; Wood B; Wu D; Lee MK; Dintzis S; Adey A; Liu Y; Eaton KD; Martins R; Stricker K; Margolin KA; Hoffman N; Churpek JE; Tait JF; King MC; Walsh T
    J Mol Diagn; 2014 Jan; 16(1):56-67. PubMed ID: 24189654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TumorNext: A comprehensive tumor profiling assay that incorporates high resolution copy number analysis and germline status to improve testing accuracy.
    Gray PN; Vuong H; Tsai P; Lu HM; Mu W; Hsuan V; Hoo J; Shah S; Uyeda L; Fox S; Patel H; Janicek M; Brown S; Dobrea L; Wagman L; Plimack E; Mehra R; Golemis EA; Bilusic M; Zibelman M; Elliott A
    Oncotarget; 2016 Oct; 7(42):68206-68228. PubMed ID: 27626691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development and validation of the JAX Cancer Treatment Profile™ for detection of clinically actionable mutations in solid tumors.
    Ananda G; Mockus S; Lundquist M; Spotlow V; Simons A; Mitchell T; Stafford G; Philip V; Stearns T; Srivastava A; Barter M; Rowe L; Malcolm J; Bult C; Karuturi RK; Rasmussen K; Hinerfeld D
    Exp Mol Pathol; 2015 Feb; 98(1):106-12. PubMed ID: 25562415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance Characteristics of a Targeted Sequencing Platform for Simultaneous Detection of Single Nucleotide Variants, Insertions/Deletions, Copy Number Alterations, and Gene Fusions in Cancer Genome.
    Park K; Tran H; Eng KW; Ramazanoglu S; Marrero Rolon RM; Scognamiglio T; Borczuk A; Mosquera JM; Pan Q; Sboner A; Rubin MA; Elemento O; Rennert H; Fernandes H; Song W
    Arch Pathol Lab Med; 2020 Dec; 144(12):1535-1546. PubMed ID: 32045275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT): A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology.
    Cheng DT; Mitchell TN; Zehir A; Shah RH; Benayed R; Syed A; Chandramohan R; Liu ZY; Won HH; Scott SN; Brannon AR; O'Reilly C; Sadowska J; Casanova J; Yannes A; Hechtman JF; Yao J; Song W; Ross DS; Oultache A; Dogan S; Borsu L; Hameed M; Nafa K; Arcila ME; Ladanyi M; Berger MF
    J Mol Diagn; 2015 May; 17(3):251-64. PubMed ID: 25801821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing.
    Wagle N; Berger MF; Davis MJ; Blumenstiel B; Defelice M; Pochanard P; Ducar M; Van Hummelen P; Macconaill LE; Hahn WC; Meyerson M; Gabriel SB; Garraway LA
    Cancer Discov; 2012 Jan; 2(1):82-93. PubMed ID: 22585170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
    Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
    Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of a next-generation sequencing assay for clinical molecular oncology.
    Cottrell CE; Al-Kateb H; Bredemeyer AJ; Duncavage EJ; Spencer DH; Abel HJ; Lockwood CM; Hagemann IS; O'Guin SM; Burcea LC; Sawyer CS; Oschwald DM; Stratman JL; Sher DA; Johnson MR; Brown JT; Cliften PF; George B; McIntosh LD; Shrivastava S; Nguyen TT; Payton JE; Watson MA; Crosby SD; Head RD; Mitra RD; Nagarajan R; Kulkarni S; Seibert K; Virgin HW; Milbrandt J; Pfeifer JD
    J Mol Diagn; 2014 Jan; 16(1):89-105. PubMed ID: 24211365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
    Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
    J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of Treatment-Focused Tumor Sequencing to Screen for Germline Cancer Predisposition.
    Lau TTY; May CM; Sefid Dashti ZJ; Swanson L; Starks ER; Parker JDK; Moore RA; Tucker T; Bosdet I; Young SS; Santos JL; Compton K; Heidary N; Hoang L; Schrader KA; Sun S; Kwon JS; Tinker AV; Karsan A
    J Mol Diagn; 2021 Sep; 23(9):1145-1158. PubMed ID: 34197922
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.
    Lee SH; Lee B; Shim JH; Lee KW; Yun JW; Kim SY; Kim TY; Kim YH; Ko YH; Chung HC; Yu CS; Lee J; Rha SY; Kim TW; Jung KH; Im SA; Moon HG; Cho S; Kang JH; Kim J; Kim SK; Ryu HS; Ha SY; Kim JI; Chung YJ; Kim C; Kim HL; Park WY; Noh DY; Park K
    Cancer Res Treat; 2019 Jan; 51(1):211-222. PubMed ID: 29690749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The differential diagnoses of uterine leiomyomas and leiomyosarcomas using DNA and RNA sequencing.
    Mas A; Alonso R; Garrido-Gómez T; Escorcia P; Montero B; Jiménez-Almazán J; Martín J; Pellicer N; Monleón J; Simón C
    Am J Obstet Gynecol; 2019 Oct; 221(4):320.e1-320.e23. PubMed ID: 31121144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.
    Frampton GM; Fichtenholtz A; Otto GA; Wang K; Downing SR; He J; Schnall-Levin M; White J; Sanford EM; An P; Sun J; Juhn F; Brennan K; Iwanik K; Maillet A; Buell J; White E; Zhao M; Balasubramanian S; Terzic S; Richards T; Banning V; Garcia L; Mahoney K; Zwirko Z; Donahue A; Beltran H; Mosquera JM; Rubin MA; Dogan S; Hedvat CV; Berger MF; Pusztai L; Lechner M; Boshoff C; Jarosz M; Vietz C; Parker A; Miller VA; Ross JS; Curran J; Cronin MT; Stephens PJ; Lipson D; Yelensky R
    Nat Biotechnol; 2013 Nov; 31(11):1023-31. PubMed ID: 24142049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics.
    Eijkelenboom A; Tops BBJ; van den Berg A; van den Brule AJC; Dinjens WNM; Dubbink HJ; Ter Elst A; Geurts-Giele WRR; Groenen PJTA; Groenendijk FH; Heideman DAM; Huibers MMH; Huijsmans CJJ; Jeuken JWM; van Kempen LC; Korpershoek E; Kroeze LI; de Leng WWJ; van Noesel CJM; Speel EM; Vogel MJ; van Wezel T; Nederlof PM; Schuuring E; Ligtenberg MJL
    Virchows Arch; 2019 Jun; 474(6):673-680. PubMed ID: 30888490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours.
    Singh RR; Patel KP; Routbort MJ; Aldape K; Lu X; Manekia J; Abraham R; Reddy NG; Barkoh BA; Veliyathu J; Medeiros LJ; Luthra R
    Br J Cancer; 2014 Nov; 111(10):2014-23. PubMed ID: 25314059
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Close correlation of copy number aberrations detected by next-generation sequencing with results from routine cytogenetics in acute myeloid leukemia.
    Vosberg S; Herold T; Hartmann L; Neumann M; Opatz S; Metzeler KH; Schneider S; Graf A; Krebs S; Blum H; Baldus CD; Hiddemann W; Spiekermann K; Bohlander SK; Mansmann U; Greif PA
    Genes Chromosomes Cancer; 2016 Jul; 55(7):553-67. PubMed ID: 27015608
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of a Hybrid Capture-Based Pan-Cancer Panel for Analysis of Treatment Stratifying Oncogenic Aberrations and Processes.
    Kroeze LI; de Voer RM; Kamping EJ; von Rhein D; Jansen EAM; Hermsen MJW; Barberis MCP; Botling J; Garrido-Martin EM; Haller F; Lacroix L; Maes B; Merkelbach-Bruse S; Pestinger V; Pfarr N; Stenzinger A; van den Heuvel MM; Grünberg K; Ligtenberg MJL
    J Mol Diagn; 2020 Jun; 22(6):757-769. PubMed ID: 32205293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comprehensive routine diagnostic screening to identify predictive mutations, gene amplifications, and microsatellite instability in FFPE tumor material.
    Steeghs EMP; Kroeze LI; Tops BBJ; van Kempen LC; Ter Elst A; Kastner-van Raaij AWM; Hendriks-Cornelissen SJB; Hermsen MJW; Jansen EAM; Nederlof PM; Schuuring E; Ligtenberg MJL; Eijkelenboom A
    BMC Cancer; 2020 Apr; 20(1):291. PubMed ID: 32264863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Novel Next-Generation Sequencing-Based Approach for Concurrent Detection of Mitochondrial DNA Copy Number and Mutation.
    Zhou K; Mo Q; Guo S; Liu Y; Yin C; Ji X; Guo X; Xing J
    J Mol Diagn; 2020 Dec; 22(12):1408-1418. PubMed ID: 33011442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.